Summary
CRSP Chart
Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy
Crispr Therapeutics AG remains a Strong Buy, driven by forthcoming revenue following Casgevy's FDA/EMA approvals and a robust, expanding pipeline targeting high-value indications. CRSP's commercial launch of Casgevy is progressing, with their share of a $100M+ 2025 total revenue expectation, and significant growth expected into 2026. The pipeline's cardiovascular assets (CTX310/320) show promising early efficacy, with huge addressable markets and the potential to disrupt standard-of-care regimens.
Meet the Beaten-Down Biotech Stock Cathie Wood Loves That Wall Street Says May Soar 50%
Cathie Wood aims to identify innovators and invest in them early in their stories. Wood has been regularly adding to her position in this stock, and it's one of her top holdings.
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics (CRSP) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Crispr Therapeutics AG (CRSP) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Crispr Therapeutics AG ever had a stock split?
Crispr Therapeutics AG Profile
| - Industry | - Sector | Samarth Kulkarni CEO | NASDAQ (NMS) Exchange | H17182108 CUSIP |
| CH Country | 393 Employees | - Last Dividend | 19 Jul 2016 Last Split | 19 Oct 2016 IPO Date |
Overview
CRISPR Therapeutics AG is a pioneer in the field of gene editing, leveraging its sophisticated Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform to develop innovative gene-based medicines for a variety of serious human diseases. Founded in 2013 and based in Zug, Switzerland, CRISPR Therapeutics is at the forefront of medical research in gene editing technology, particularly CRISPR/Cas9, which enables precise and targeted modifications to genomic DNA. With a focus on addressing unmet medical needs in hemoglobinopathies, immune-oncology, autoimmune diseases, in vivo treatments, and type 1 diabetes, the company is dedicated to advancing a diverse portfolio of therapeutic programs aimed at providing transformative treatments for patients worldwide.
Products and Services
- CASGEVY
- CAR T Cell Therapies: CTX112 and CTX131
- In Vivo Gene Editing: CTX310 and CTX320
- VCTX211
An ex vivo CRISPR/Cas9 gene-edited cell therapy, CASGEVY is CRISPR Therapeutics’ lead product candidate designed to treat patients with transfusion-dependent beta-thalassemia, severe sickle cell disease, and other hemoglobinopathies. This innovative treatment edits a patient's hematopoietic stem and progenitor cells to induce high levels of fetal hemoglobin in red blood cells, potentially alleviating symptoms of these severe genetic diseases.
CRISPR Therapeutics is also developing CAR T cell therapies, including CTX112, targeting CD19, and CTX131, targeting CD70. These therapies are designed for the treatment of various oncology and autoimmune indications, utilizing engineered T cells to recognize and attack cancer cells or modulate immune responses in autoimmune diseases.
In a groundbreaking approach to cardiovascular disease treatment, CRISPR Therapeutics offers CTX310 and CTX320. These in vivo gene editing therapies target angiopoietin-like protein 3 and lipoprotein, respectively, disrupting the validated targets to address underlying causes of cardiovascular conditions.
VCTX211 represents an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate focused on the treatment of Type 1 Diabetes (T1D). This advanced therapeutic aims to offer a novel approach to managing T1D by addressing the immune system's role in the disease's development and progression.
In addition to its innovative product pipeline, CRISPR Therapeutics AG has formed strategic partnerships with leading companies in the biotech sector, including Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. These collaborations are instrumental in advancing CRISPR/Cas9 and other gene editing technologies, furthering the company's mission to provide groundbreaking treatments for diseases with significant unmet need.
Contact Information
